Cell News and Research

RSS

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Cardium Therapeutics today announced the publication of positive findings from the Company's Matrix Phase 2b clinical study.

9 Mar 2011

New study shows excess hospitalization costs for homeless people

Homeless patients cost about $2,500 more per hospital stay than the average patient, according to a new study by researchers at St. Michael's Hospital.

9 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Yakult Honsha, AEZS sign agreement to develop, commercialize and license perifosine

Aeterna Zentaris Inc. and Yakult Honsha Co., Ltd. today announced the signing of an exclusive development, commercialization and licensing agreement for the development, registration and marketing of perifosine, Aeterna Zentaris' lead anti-cancer compound, for Japan.

9 Mar 2011

Trade name ‘The Stem Cell Group’ registered for Celulas Genetica

Emerging Healthcare Solutions, Inc. announced today that it registered a trade name, "The Stem Cell Group," for use in marketing and branding its subsidiary company, Celulas Genetica.

9 Mar 2011

Multiple target therapy may treat HER2-positive breast cancers

Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center investigators.

9 Mar 2011

Postdoctoral research fellows receive Pancan- AACR Pathway to Leadership Grants

The Pancreatic Cancer Action Network and the American Association for Cancer Research have awarded Jennifer M. Bailey, Ph.D., and E. Scott Seeley, M.D., Ph.D., the 2011 Pancreatic Cancer Action Network - AACR Pathway to Leadership Grants.

9 Mar 2011

Sanfilippo syndrome compromises blood-brain barrier, leads to brain damage

A study into the effects of Sanfilippo Syndrome type B (MPS III B) has found that the barrier responsible for protecting the brain from the entry of harmful blood-borne substances is structurally and functionally damaged by the devastating disease. University of South Florida researchers identified damage in specific brain structures involved in the pathology of MPS III B, one of four Sanfilippo syndromes, all of which are inherited diseases of metabolism.

9 Mar 2011

Parkinson's disease medication turns on critical gene, protects brain cells

In a major breakthrough in the battle against Parkinson's disease, researchers at the University of Colorado School of Medicine have discovered a drug that stops the progression of the degenerative illness in mice and is now being tested in humans.

9 Mar 2011

Therapeutic potential of iPS cells may be limited by reprogramming errors and genomic instability

In the past few months, a slew of papers have indicated that the therapeutic potential of a promising type of stem cell, called induced pluripotent stem (iPS) cells, might be limited by reprogramming errors and genomic instability. iPS cells are engineered by reprogramming fully differentiated adult cells, often skin cells, back to a primitive, embryonic-like state.

9 Mar 2011

Pulse Health's Revelar device helps minimize free radical damage

Pulse Health announces Revelar the first non-invasive device to help healthcare professionals and their patients measure aldehydes and help minimize free radical damage. Revelar is breakthrough breath technology that accurately detects and measures the presence of aldehydes, which are indicators of free radical damage in the body.

9 Mar 2011

LRI announces 12 new research grants to drive innovation in lupus

The Lupus Research Institute today announced the award of 12 new research grants, building on its decade-long commitment to drive innovation and discover novel approaches to understand and treat one of the world's most confounding and elusive diseases - lupus.

9 Mar 2011

Allergy Asthma Research Institute, Forest Labs join SAFE-BioPharma

In a move to improve efficiency by reducing paper in their respective operations, Forest Laboratories and the Allergy Asthma Research Institute have joined SAFE-BioPharma Association. They now have access to the SAFE-BioPharma® digital identity and signature standard, used throughout the biopharmaceutical industry to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents.

9 Mar 2011

NHMRC awards $38.4M for cancer and blood cell research

Institute research into how cancer develops and blood cell production and function will today be awarded $38.4 million under the National Health and Medical Research Council's (NHMRC) program grants scheme.

9 Mar 2011

Autologous fat stem cell therapies for eternal life

Whereas formerly often only the symptoms of age were treated in cosmetic medicine, autologous stem cell-assisted regenerative therapies take a more comprehensive approach: the abundant stem cells in fat tissue are extracted and introduced in the body. The autologous stem cells then exert their regenerative power in the body where needed. Organs and tissues are regenerated and rejuvenated; even degenerative and chronic diseases are treatable.

9 Mar 2011

Text messaging effectively intervenes during smoking urges

A pair of related studies on smoking cessation by researchers at the University of Oregon and other institutions have isolated the brain regions most active in controlling urges to smoke and demonstrated the effectiveness of text-messaging to measure and intervene in those urges.

9 Mar 2011

Research: Eating disorders more prevalent among Muslim adolescents than Christian

The incidence of eating disorders was found to be 2.3-fold higher among Muslim adolescents than among their Christian classmates. Similarly, body dissatisfaction was 1.8-fold higher in the former group.

9 Mar 2011

Chemotherapy drugs also kill malaria parasite

A group of researchers from EPFL's Global Health Institute (GHI) and Inserm (Institut National de la Sant- et de la Recherche M-dicale, the French government agency for biomedical research) has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria. The discovery could quickly open up a whole new strategy for combating this deadly disease.

9 Mar 2011

FDA accepts BMY and AstraZeneca's dapagliflozin NDA for review

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for dapagliflozin, an investigational compound for the treatment of adults with type 2 diabetes mellitus.

9 Mar 2011

Study finds increase in oral tongue cancer incidence in young US white females

A UNC study released this week in the Journal of Clinical Oncology finds an increasing incidence of squamous cell carcinoma of the oral tongue in young white females in the United States over the last three decades.

9 Mar 2011